Process Robustness: Development to Life Cycle Management. Presented By J. Richard Creekmore US Technology Manager AstraZeneca Pharmaceuticals
|
|
- Brice Higgins
- 6 years ago
- Views:
Transcription
1 Process Robustness: Development to Life Cycle Management Presented By J. Richard Creekmore US Technology Manager AstraZeneca Pharmaceuticals
2 Introduction You ve heard it before: Complaints about the robustness of the manufacturing processes used to manufacture your products. Process robustness leads to: Higher efficiency Increased profit Less regulatory hassles Happier employees Robustness can be done right if you start at the beginning of development. We have the tools to do it better and more efficiently. Starts with ICH Q8 and Q9
3 Process Robustness Principles 1. Definition 2. Critical Quality Attributes 3. Critical Process Parameters 4. Process and Material Variability 5. Tolerance Limits 6. Operating Ranges: Normal, Known operating space, relation to ICH Q8
4 What is robustness? The ability of a process to demonstrate acceptable quality and performance while tolerating variability in inputs. Many factors affect robustness: Formulation Materials Measurements People Environmental conditions Place in development process
5 Critical Quality Attributes (CQAs) CQAs are quantifiable properties that are critical to the safety, efficacy, and purity of the intermediate and final product. Other attributes may be described as Key Attributes, not critical, but important in the manufacture of the product. Some disagreement about what is and isn t CQA. Each company has its own philosophy. Important to be able to defend list of CQAs for each product. Unnecessary CQAs can be troublesome-choose carefully.
6 Critical Quality Attributes Examples (tablets) Product Attributes Assay Content Uniformity Dissolution Appearance Tablet Hardness Thickness Weight Uniformity Friability Yield Moisture Blend Particle Size Stability CQA X X X X X
7 Critical Process Parameters (CPP s) Process input variable that must be maintained within a proven acceptable or predetermined range in order to ensure that an intermediate or final product will be within its CQA limits. Generally does not include factors that are related to efficiency, yield, safety/health/environment, business objectives unless the factor affects product quality or is a GMP concern, e.g. yield.
8 Variability Sources include equipment, raw materials, human factors, testing methods, manufacturing procedures. Important to control as many as possible Understanding raw materials and specification is important: compendial testing, manufacturing process, stability, interactions. Procedures and methods: Must be clear and easy to reproduce.
9 Tolerance Limits Understanding of tolerances comes from experimentation (DOE) and experience. Best to have ranges for as many variables as possible, but not practical. Decide which ones are more important (QRA) Some cannot be determined because no method can determine the difference. Only downstream processing and testing might work, e.g. blend uniformity of a non-flowing mixture.
10 Operating Ranges Zone Proven acceptable range or design space may not fill the operating range completely
11 Operating Ranges Zone marked in Yellow ( Zone) represents the level of assurance that the normal operating is far/near the level of failure. Development plan should be designed to maximize this distance. Maximizing this distance will generate process understanding. Risk assessment, statistical tools, DOE (ICH Q9) are helpful in understanding which processing parameters need more work in maximizing the distance between the NOR and PAR ( Zone).
12 Developing a robust process- Development During development knowledge increases from near zero to nearly complete. Preferred tool to document and guide development teams is risk assessment at key stages ICH Q9.
13 ICH-Q9 Initiate Risk Management Process Risk Assessment Risk Identification Re-evaluation Risk Analysis Risk Evaluation Risk Management tools Risk Control Risk Reduction Risk Acceptance unacceptable Risk Communication Risk Review Risk Communication acceptable Risk Acceptance Output / Results of the Risk Management Process Review Events
14 Steps for Developing A Robust Product 1. Form the team 2. Define the process (process flow diagram, inputs, outputs) 3. Prioritize experiments 4. Analyze measurement capability 5. Identify functional relationships 6. Identify critical quality attributes and critical process parameters 7.Identify the design space.
15 Steps for Developing A Robust Product 1. Form the team Teams should be multidisciplinary including formulators, engineers, analysts, statisticians, and other scientists. Team membership should be flexible as development proceeds. Team should include those with knowledge of development and large scale manufacturing Team s focus should change as development proceeds over time.
16 Steps for Developing A Robust Product 2. Define the process Process takes shape as development progresses Process diagram is a must; basic version in IND Process diagram should reflect process at a given time Process diagram basis for QRA and other activities related to product Helps in focusing the CPPs and CQAs
17 Process Diagram
18 Steps for Developing A Robust Product 3. Prioritize experiments Speeds development. Provides clarity. More efficient use of resources. Quality Risk Assessment (FMEA, PHA, or similar) Helps in prioritizing areas needing work Provides written record of thinking into developing product Another history of development process Reports
19 ICH-Q9 Risk Assessment Initiate Risk Management Process Risk Identification REPORTS DATA EXPERIMENTS Re-evaluation Risk Analysis Risk Evaluation Risk Management tools Risk Control Risk Reduction Risk Acceptance unacceptable Risk Communication Risk Review Risk Communication acceptable Risk Acceptance Output / Results of the Risk Management Process Review Events
20 PHA Example more appropriate for early stages Uncertain Event Handing of high hazard materials in Product Development Risk/Opportunity Description Example: Decontamination procedures not clearly defined Threat Opportunity Probability Impact T H H 16 Product Mitigation or Maximization Review decontamination procedures for other sites, put procedures in place for decontamination which are proven to eliminate risk for decontamination Wider training required, risk of inexperienced operators and eliminate fear of unknow Further monitoring required for clarification that bags can be used reproducibly Documentation: protection of batch records, laptops, log books, calculators, pens, etc T M L 6 Completed department training T M M 9 Budgets need to be agreed upon for further testing to ensure consistent use of containment and generation of data from monitoring. Is there a cheaper way to get monitoring? T M L 6 More investigation required Mitigation procedures if containment breached, fogger use, evacuation of room, training on procedures, containing Safety, working alone New containment design speeds processing by 50% T H H 16 O H H 16 Portable door entry system, modular degowning rooms Document time savings by manufacturing batches, report results to R&D management, present results at meetings like Interphex
21 FEMA Example More appropriate for later stages
22 Summary bar graph FEMA example Needs more attention
23 Steps for Developing A Robust Product 4. Analyze measurement capability Understanding of the measurement capability is key to process understanding and troubleshooting Analytical procedure capabilities are generally well known. Process measurements such as temperature, speed, etc are more exact. Other types of measurements may not correlate as well, e.g. motor load analysis. Some measurement values may need mathematical treatment.
24 Steps for Developing A Robust Product 5. Identify functional relationship between inputs and outputs Key to understanding process. Relationship is usually complex. Requires Design of Experiments (DOE) to understand or at least relate input and outputs DOE saves time and resources; more efficient than studying 1 variable at a time. Helps in planning experiments and using resources.
25 Steps for Developing A Robust Product 6. Confirm CQAs and CPPs CPPs are developed from Steps 2 & 5. List becomes more complete during development. List should be complete when manufacturing ICH stability batches. May need adjustment at tech transfer-more work at small scale maybe needed later based on large scale experience (stuff happens!). Clearly noted in development reports especially final development report and tech transfer report.
26 Steps for Developing A Robust Product 7. Identify the Design Space Culminates from all development work. Should be complete or nearly complete for tech transfer. Develops over the development process. May change during tech transfer. Information needed for NDA/MAA. Key to understanding manufacturing process along with gaining efficiencies and cost savings.
27 Technology Transfer Success depends on how well characterized the formulation and process are at time of tech transfer. Changes to some operating parameters may require change during tech transfer. Should challenge operating parameters, CPPs, and CQAs. Based on tech transfer data, adjustments to operating parameters, CPPs, and CQAs should be done before validation. After validation, a new risk assessment should be completed (Did I mention ICH Q9?).
28 Manufacturing Process Robustness Very important to maintain to keep costs down and minimize risk of OOSs, 483s, shortages, etc. Requires effort and commitment from management. Has significant payoff when problems do arise. 3 parts to maintaining robustness Monitoring Product improvement Facility/plant improvement
29 Manufacturing Process Robustness: Monitoring (1) Important part of manufacturing, but not commonly done correctly - usually done as a reactionary response, not as a proactive activity. Data and labor intensive (easier to do over time). Requires participation of many disciplines, e.g. engineers, analysts, statisticians, QA, etc. Typical tools used are: C p /C p k Control charts for key values (process parameters and product characteristics) Trend charts
30 Manufacturing Process Robustness: Monitoring (2) A tool that could be better used: Quality Risk Assessment: Continues QRA from Tech Transfer (ICH Q9) Organizes improvement and troubleshooting projects Should be held at regular intervals and after any improvements or changes Brings out hidden problems Prioritizes product improvement projects Creates a written record of projects related to product
31 Manufacturing Process Robustness: Product Improvement Problems identified by OOSs, trending, or QRAs. Root cause must be identified. Tools for investigation: QRA reports Ishikawa diagrams Kepner-Tregoe Statistical analysis: trending and other data Pareto charts
32 Ishikawa Diagram
33 Manufacturing Process Robustness: Facility Improvement Plan Monitoring and improvement of items related to all products (common items). These include: Personnel training/assessment Facilities (e.g. layout, systems) Materials Calibration and Maintenance Batch records (Are they clear? More detail doesn t lead to better execution.) Quality program-integration of findings. Studies of equipment variation vs operator variation (Repeatabity & Reproducability).
34 Conclusion (1) Robustness is the ability of a process to demonstrate acceptable quality and performance while tolerating variability in inputs. Process robustness starts at beginning of the development and continues through the life of the product. Principles of ICH Q8 and Q9 are key to developing and maintaining a robust process. Critical Quality Attributes are related to safety, efficacy, and purity; other attributes maybe described as key attributes.
35 Conclusion (2) Critical process parameters are process input variables that ensure the product/intermediate within CQA limits Steps for developing a robust product 1. Form the team 2. Define the process 3. Prioritize experiments 4. Analyze measurement capability 5. Identify functional relationships 6. Identify critical quality attributes and critical process parameters 7.Identify the design space.
36 Conclusion (3) Development of a robust product continues into tech transfer and validation-changes to CPPs, CQAs, and key parameters may be necessary at scale-up. Robustness is maintained by: Monitoring Product improvement Facility improvement Developing and maintaining robustness is a process that requires long term commitment.
37 References (1) 1. Process Robustness, PQRI White Paper, Draft 2. Process Robustness - A PQRI White Paper, Pharmaceutical Engineering, November/December 2006, Vol. 26, No. 6. ( Making Risk Assessment Part of Technology Transfer, Presentation at Interphex 2012, New York, New York, 1 May How to Define Design Space, Lynn Torbeck, pharmstat.com/files/design-space.ppt
38 References (2) 6. Quality Risk Management, ICH Q9, /Scientific_guideline/2009/09/WC pdf 7. Quality Risk Management for the Pharmaceutical Industry, Kirupakar, B.R., 8. Pharmaceutical Development, ICH Q8, s/guidelines/quality/q8_r1/step4/q8_r2_guideline.pdf
Control Strategy. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 Control Strategy International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of this session
More informationQuality by Design (QbD)
Evaluating the Critical Quality attributes & Critical Process Parameters-A Case Study-Tablets GMP International Workshop February 20/21, 2008 Mumbai, India Mukund Yelvigi Director, Therapeutic Area Management,
More informationA COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION
A COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION By Mark Mitchell, Principal Consultant, Process and Engineering, Pharmatech Associates, Inc. PHARMATECH WHITE PAPER.DOCX
More informationICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment
ICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment Thomas Schultz, Ph.D. Director, Regulatory Sciences Johnson & Johnson September 12, 2007 Presentation
More informationThe Role of Quality Risk Management in New Drug Development and Manufacturing
The Role of Quality Risk Management in New Drug Development and Manufacturing CASSS CMC Strategy Forum Bethesda, MD July 27, 2009 Terrance Ocheltree, RPh, PhD Pharmaceutical Assessment Lead (Acting) Office
More informationStage 3 - Process Validation: Measuring what matters
Stage 3 - Process Validation: Measuring what matters Trevor Schoerie - PharmOut A quote. The company that fails is the company that comes to us and says Just tell us what to do and we will do it. The company
More informationPMDA Views on Applying Continuous Manufacturing to Pharmaceutical Products for Industry (provisional draft)
PMDA Views on Applying Continuous Manufacturing to Pharmaceutical Products for Industry (provisional draft) March 30, 2018 Pharmaceuticals and Medical Devices Agency Innovative Manufacturing Technology
More informationA Framework and Case Study for Implementing the New Process Validation Guidance
A Framework and Case Study for Implementing the New Process Validation Guidance Presented By Bikash Chatterjee President and Chief Technology Officer Pharmatech Associates Agenda Introduction Comparing
More informationProcess Design Risk Management A Proactive Approach
Page 1 of 7 Guest Column August 30, 2017 Process Design & Risk Management A Proactive Approach By Sandra Wassink, Principal Process Engineer, Pharmatech Associates The FDA has given us the green light
More informationRegulatory Assessment
Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal
More informationImplementation of QBD for Analytical Methods - Session Introduction -
Implementation of QBD for Analytical Methods - Session Introduction - Sonja Sekulic January 24, 2014 Quality by Design (QbD) A Systematic Approach ICH Q8(R2) Product Profile Define quality target product
More informationQbD (Quality by Design) Has industry benefited from this? WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting There are many facets to engineering for a healthier world. It is important to understand what surrounds us today and look into what we believe will surround us
More informationContent PART I: ANDA Roadmap PART II: Understanding of CPPs & CQAs PART III: Scale-Up and Technology Transfer PART IV: Process Validation & Sampling 2
EMA, FDA- ANDA Readiness -OSD Generics Solution Post Formulation Development Horch Guo, May. 2016, Changzhou, China Hongxing.guo@yahoo.com Content PART I: ANDA Roadmap PART II: Understanding of CPPs &
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationHow to Identify Critical Quality Attributes and Critical Process Parameters
How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,
More informationShort review on Quality by design: A new Era of Pharmaceutical drug development
International Journal of Drug Development & Research July-September 2012 Vol. 4 Issue 3 ISSN 0975-9344 Available online http://www.ijddr.in Covered in Official Product of Elsevier, The Netherlands SJR
More informationPROCESS VALIDATION ANSM 2015 FDA 2011
PROCESS VALIDATION ANSM 2015 FDA 2011 PBE-Expert Inc CANADA Training Company Agreement CPMT #0059104 Qualified Consultant At the measure 2 of the Levier Program PBE, Training Company Agreement CPMT #0059104
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationResearch and Reviews: Journal of Pharmacy and Pharmaceutical Sciences
Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences Pharmaceutical Quality by Design: A New Approach in Product Development. Ashwini Gawade 1 *, Satyam Chemate 1, and Ashwin Kuchekar
More informationIdentifying and Controlling CPPs and CMAs
March 2018, BioPharm International Publication Identifying and Controlling CPPs and CMAs Thomas A. Little Ph.D. 2/22/2018 President/CEO Thomas A. Little Consulting, BioAssay Sciences 12401 N Wildflower
More informationA Comprehensive Review on Quality by Design (QbD) in Pharmaceuticals
Review Article Hardik Patel* 1, Shraddha Parmar 1, Bhavna Patel 1 1 Post Graduate Department of Pharmaceutical Sciences, Sardar Patel University, Vallabh Vidyanagar, Gujarat, India. *Corresponding author
More informationValidation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.
Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals. 1 Analytical Method Validation: 1..1 Philosophy: Method validation is
More informationProcess Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010
Process Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010 Overview Goal of Manufacturing Central Question: Why is process
More informationSeptember 21, Dear Sir or Madam:
September 21, 2017 US Food and Drug Administration Division of Dockets Management (HFA-305) 5630 Fishers Lane, Rm 1061 Rockville, Maryland 20852 via electronic submission Subject: Docket No. FDA-2017-N-2697
More informationProcess Validation Guidelines. Report highlights 23 rd February 2018
Process Validation Guidelines Report highlights 23 rd February 2018 Process validation is an important element of pharmaceutical quality system An effective system provides assurance of the continued capability
More informationProduct, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA
Product, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA Naheed Sayeed Manager, Technical Operations Process Validation, Apotex Inc. 1 Process Validation Life Cycle Stage
More informationAuditing Your Laboratory for Compliance with the FDA Dietary Supplement GMP s
Tech Tip 0020 With the advent of the cgmp s, the majority of companies are increasing the frequency of their outsourced analytical testing. But the GMPs are just that, Good Manufacturing Practices, and
More informationManual 058 Out of Specification Results Investigation
1 Purpose The purpose of this Guideline is to provide guidance for the investigation and response to Out of Specification (OOS) laboratory test results. 2 Scope and Applicability This Guideline applies
More informationPQLI Control Strategy Model and Concepts
J Pharm Innov (008) :95 104 DOI 10.1007/s147-008-905-1 PRODUCT QUALITY LIFECYCLE IMPLEMENTATION (PQLI) INNOVATIONS PQLI Control Strategy Model and Concepts Bruce Davis Line Lundsberg Graham Cook Published
More informationPAT for the On-line Characterization of Continuous Manufacturing Systems
PAT for the On-line Characterization of Continuous Manufacturing Systems Thomas O Connor, Ph.D. Office of Pharmaceutical Science FDA/PQRI Conference: Innovation in Manufacturing and Regulatory Assessment
More informationApplication of Quality by Design (QbD) in product development. James E. Polli September 16, 2015
Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route
More informationQuality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Quality Implementation Working Group on Q8, Q9 and Q10 & Current version dated June
More informationStatistics in Validation. Tara Scherder CSO Supply, Arlenda, Inc
Statistics in Validation 05 Arlenda Tara Scherder CSO Supply, Arlenda, Inc IVT Validation Week Philadelphia, PA Oct 7,05 Agenda Evolution of Validation 0 FDA Guidance Why Use Statistics Stage Process Design
More informationProduct Robustness: Reducing Variability and Ensuring Delivery of Superior Quality Products to Patients
Product Robustness: Reducing Variability and Ensuring Delivery of Superior Quality Products to Patients Dafni Bika, Jennifer Walsh and Tara Nestor Global Manufacturing Science and Technology Bristol-Myers
More informationImplementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development. S Betterman 15Apr2015
Implementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development S Betterman 15Apr2015 Agenda Background Implementation Strategy Infrastructure Building Project Application
More informationManual 029 Deviation Management
1 Purpose The purpose of this guideline is to outline the requirements for the reporting, investigation and handling of individual deviations, and to outline a systematic approach for the trending of deviations,
More informationá1225ñ VALIDATION OF COMPENDIAL PROCEDURES
1640 á1224ñ Transfer of Analytical Procedures / General Information USP 39 THE ANALYTICAL PROCEDURE The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst
More informationQuality Risk Management
Implementation of ICH Q8, Q9, Q10 Quality Risk Management International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of
More informationGuidance for Industry
Guidance for Industry Q8, Q9, and Q10 Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationApplication of Quality by Design in formulation and process Development
21 st EAFP Annual Conference, Quality Assurance in Pharmacy Education, May 14-16, 2015 Application of Quality by Design in formulation and process Development Stavros N. Politis, Pharmacist, MSc, PhD Laboratory
More informationQbD and the New Process Validation Guidance
Page 1 of 6 Published on Pharmaceutical Processing (http://www.pharmpro.com) Home > QbD and the New Process Validation Guidance QbD and the New Process Validation Guidance Bikash Chatterjee and Wai Wong,
More information2nd FDA/PQRI Conference on Advancing Product Quality
2nd FDA/PQRI Conference on Advancing Product Quality Generic Pharma Perspective on the Identification of Critical Quality Attributes and Critical Process Parameters Bruce D. Johnson, Ph.D. Vice President
More informationManaging Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA
Managing Quality in Pharmaceutical Industry Using Six Sigma Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA Outlines Pharmaceutical Manufacturing Process and Drug Product Quality. Process Excellence Approach
More informationPerspectives on Method Validation: Importance of Adequate Method Validation
Perspectives on Method Validation: Importance of Adequate Method Validation Heather Bridwell, Vikas Dhingra, Daniel Peckman, Jennifer Roark and Thomas Lehman The appropriate validation of analytical methods
More informationWHO DRAFT PHARMACEUTICAL DEVELOPMENT FOR MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS
23 April 2008 Quality Assurance Programme Quality Assurance and Safety: Medicines (QSM) Department of Medicines Policy and Standards (PSM) World Health Organization CH-1211 Geneva 27 Switzerland WHO DRAFT
More informationQbD In Drug Development. Mathew Cherian Ph.D. Director & Senior Fellow Pfizer, USA
QbD In Drug Development Mathew Cherian Ph.D. Director & Senior Fellow Pfizer, USA The Origin of QbD The concept of Quality by Design (QbD) was introduced by Romanian born US engineer Joseph Juran QbD was
More informationGENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES
July 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES REVISED
More informationQbD BASED SCALE UP SERVICES THE DPT LABS APPROACH
DPT Thought Leadership Issue 14: 4 th in a Series QbD BASED SCALE UP SERVICES THE DPT LABS APPROACH INTRODUCTION This paper describes the approach and benefits of using DPT Labs QbD Scale Up service and
More informationJFS-A/B/C Standards <Manufacturing> [Interpretations]
JFS-A/B/C Standards [Interpretations] JFS-A Standard Ver. 1.1 JFS-B Standard Ver. 1.1 JFS-C Standard Ver. 2.2 Japan Food Safety Management Association September 15, 2017 Table of Contents
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More informationPMDA Perspective: Regulatory Updates on Process Validation Standard
CMC Strategy Forum Japan 2014 Tokyo, Japan, December 8-9, 2014 PMDA Perspective: Regulatory Updates on Validation Standard Kazunobu Oyama, PhD Office of Cellular and Tissue-based Products PMDA, Japan Disclaimer:
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More informationQuality by Design (QbD) : A new concept for development of quality pharmaceuticals
Available online on www.ijpqa.com International Journal of Pharmaceutical Quality Assurance; 4(2); 13-19 Research Article ISSN 0975 9506 Quality by Design (QbD) : A new concept for development of quality
More informationThe long anticipated draft of the FDA s
This article provides an overview of the draft guidance, the key changes in relation to the 1987 guidance, and reviews its potential impact on the current industry approaches to science- and risk-based
More informationInternational Journal of Pharmaceutical and Medicinal Research
Review article A review on process validation Int. J. Pharm. Med. Res. 2014; 2(3):100-104 ISSN: 2347-7008 International Journal of Pharmaceutical and Medicinal Research Journal homepage: www.ijpmr.org
More informationEnabling Improvement through the Product Lifecycle: Change Management within a PQS
Enabling Improvement through the Product Lifecycle: Change Management within a PQS Denise DiGiulio, Senior Advisor OPQ Office of Process and Facilities PDA Chapter Meeting Melbourne, Australia April 3,
More informationProcess Validation (PV): Designing an Effective PV Program. Mike Porter Compliance Consultant Commissioning Agents Inc.
Process Validation (PV): Designing an Effective PV Program Mike Porter Compliance Consultant Commissioning Agents Inc. (CAI) 24Apr2013 Agenda Process Validation Background Stage 1: Process Design Stage
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Medicinal Products Quality, Safety and Efficacy Brussels, 6 February 2014 SANCO/TSE/ The received contributions together with the identity of
More informationWHO guidelines on quality risk management
Annex 2 WHO guidelines on quality risk management 1. Introduction 62 1.1 Background and scope 62 1.2 Principles of quality risk management 64 2. Glossary 67 3. Quality risk management process 70 3.1 Initiating
More informationQbD implementation in Generic Industry: Overview and Case-Study
QbD implementation in Generic Industry: Overview and Case-Study Inna Ben-Anat, QbD Strategy Leader, Teva Pharmaceuticals IFPAC JAN 2013 R&D Three Core Components of QbD and Generic Industry: How Do They
More informationMASTER PLANNING FOR VALIDATION
MASTER PLANNING FOR VALIDATION By: Gamal Amer, Ph.D. Principal, Premier Compliance Services, Inc. 1 Process Validation: General Principles and Practices Guidance to industry issued by the FDA in January
More informationReview Article Review on Quality by Designing for Metered Dose Inhaler Product Development Santosh R. Thorat * 1, Sarika M.
Scholars Academic Journal of Pharmacy (SAJP) Sch. Acad. J. Pharm., 2015; 4(6): 324-330 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015
Ref. Ares(2015)3808922-15/09/2015 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Medicinal Products Quality, Safety and Efficacy Brussels, [date] This document is for consultation until 11
More informationJustification of Specifications (JOS): What Product and Process Development was all About. Christopher A Bravery
Justification of Specifications (JOS): What Product and Process Development was all About Christopher A Bravery cbravery@advbiols.com 1 The Importance of Characterisation 2 http://www.advbiols.com/documents/importance
More informationUnderstanding and accounting for product
Understanding and Modeling Product and Process Variation Variation understanding and modeling is a core component of modern drug development. Understanding and accounting for product and process variation
More informationDRAFT GUIDANCE DOCUMENT ADDENDUM - Quality (Chemistry and Manufacturing) Guidance: Questions and Answers
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 DRAFT GUIDANCE DOCUMENT ADDENDUM - Quality (Chemistry and Manufacturing) Guidance: Questions and Answers This guidance document is being distributed for comment
More informationProcess Validation Guideline
Process Validation Guideline Process Validation Guideline February 2018 Published by: Indian Pharmaceutical Alliance A-205 Sangam 14B S V Road, Santacruz (W) Mumbai 400 054 India E-mail: dgshah@vision-india.com
More informationCONTENTS 1 INTRODUCTION The Regulatory Focus on Quality Risk Management Objectives of Risk Assessment and Risk Management: The Key Concepts Key Terms in Relation to Risk and Risk Assessment Structure of
More informationStrategic Implantation of PAT : FDA Perspective
Strategic Implantation of PAT : FDA Perspective Moheb M. Nasr, Ph.D. CDER, FDA MOHEB.NASR@FDA.HHS.GOV IFPAC 2008 Strategic Implantation of PAT Baltimore, MD January 27, 2008 Outline The Desired State -
More informationVALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)
VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *) Guideline Title Validation of Analytical Procedures: Methodology Legislative basis Directive 75/318/EEC as amended Date of first adoption December 1996
More informationExperience with Health Canada s Approach for Post-Approval Changes. Kiran Krishnan Vice President US Regulatory Affairs September 2014
Experience with Health Canada s Approach for Post-Approval Changes Kiran Krishnan Vice President US Regulatory Affairs September 2014 Important Quotes to consider Dr. Janet Woodcock on desired state: A
More informationProcess Characterization Essentials Part I: Process
Process Characterization Essentials Part I: Process Understanding and Health Authorities Guidance Thomas A. Little Ph.D. 2/16/2017 President, Thomas A. Little Consulting, Bioassay Sciences 12401 N Wildflower
More informationCurrent Industry Practices in Manufacturing Process Validation. Russ Somma PhD
Russ Somma PhD The objectives for validation are: Demonstrate control over the process and finished product. Demonstrate that the process will consistently produce product which meets all specifications
More informationUnderstanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation
Understanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation Ying Verdi IVT LAB WEEK EUROPE June 2017 Partners in Health Since 1919 Regulatory View of Method
More informationImpact factor: 3.958/ICV: 4.10 ISSN:
Impact factor: 3.958/ICV: 4.10 ISSN: 0976-7908 312 Pharma Science Monitor 9(2),Apr-Jun 2018 PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES Journal home page: http://www.pharmasm.com
More informationLaboratory OOS Investigations The Missing Link
Laboratory OOS Investigations The Missing Link India Pharmaceutical Alliance Carmelo Rosa, Psy.D Director Division of Drug Quality I November 6-17, 2017 Indian Pharmaceutical Alliance DISCLAIMER: The views
More informationCurrent Regulatory Considerations and Challenges for Continuous Manufacturing of Pharmaceuticals
15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight V5-S3 Current
More informationGuideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission
1 2 3 25 April 2014 EMA/CHMP/BWP/187338/2014 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on process validation for the manufacture of biotechnology-derived active substances
More informationScientific and Regulatory challenges in Quality by Design (QbD) submissions
Health Santé Canada Canada Scientific and Regulatory challenges in Quality by Design (QbD) submissions Krishnan R. Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences TPD, Health Canada CVG, October 2007
More informationPAT for the On-line Characterization of Continuous Manufacturing Systems
PAT for the On-line Characterization of Continuous Manufacturing Systems Thomas O Connor, Ph.D. Office of Pharmaceutical Science FDA/PQRI Conference: Innovation in Manufacturing and Regulatory Assessment
More informationExcipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to
More informationPAI Inspections, Observations and Data Integrity
PAI Inspections, Observations and Data Integrity Krishna Ghosh, Ph.D. Office of Pharmaceutical Quality Office of Process and Facilities Center for Drug Evaluation and Research November, 2017 20 November
More informationCMC Consideration for the Development of Regenerative Medical Products
CMC Strategy Forum Japan 2018 December 4, 2018, Tokyo Marriot Hotel, Tokyo, Japan CMC Consideration for the Development of Regenerative Medical Products Kazunobu Oyama, PhD Deputy Review Director, Office
More informationNotice. Health Canada is pleased to announce the adoption of the ICH guidance Q8, Q9 and Q10 Questions & Answers (R4).
February 5, 2016 Notice Our file number: 16-100246-83 Adoption of International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Guidance:
More informationPharmaceutical control strategy what does it mean and how do we apply? Martin Warman, Martin Warman Consultancy Ltd
Pharmaceutical control strategy what does it mean and how do we apply? Martin Warman, Martin Warman Consultancy Ltd How can the words control strategy cause such debate? Means totally different things
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.1 April 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More information3 rd revised version. March Replaces the October 2005 version
Good Manufacturing Practices for the Production of Packaging Inks formulated for use on the non-food-contact surfaces of food packaging and articles intended to come into contact with food 3 rd revised
More informationICH Quality Implementation Working Group POINTS TO CONSIDER
ICH Quality Implementation Working Group POINTS TO CONSIDER ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation Document date: 16 June 2011 International Conference on Harmonisation of Technical Requirements
More informationIntroduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES
Introduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES William Garvey and Associates LLC 2016 Introduction About your instructor William (Bill) Garvey Important regulations and events Good Manufacturing
More informationMANUFACTURING CONTROL STRATEGY FOR CELL, GENE AND TISSUE PRODUCTS Christopher A Bravery
MANUFACTURING CONTROL STRATEGY FOR CELL, GENE AND TISSUE PRODUCTS Christopher A Bravery CBRAVERY@ADVBIOLS.COM 1 INTRODUCTION What is a manufacturing control strategy? Why is it important? Common issues
More informationControl strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA
Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not
More informationNIRS, PAT, RTR testing EU experience and regulatory perspective
NIRS, PAT, RTR testing EU experience and regulatory perspective Heidelberg, Germany October 2013 European Compliance Academy (ECA) Overview of the presentation General considerations Cases submitted in
More informationAIMCAL R2R Conference 11/15/2018 1
Coating Line Operations for the Production of Drug-Containing Transdermal Patches Presented by: Ken Glade Director of Engineering LTS Lohmann Therapy Systems Kenneth.glade@lts-corp.com +1 (973) 396-5384
More informationPost Approval Changes & Product Lifecycle Management
Post Approval Changes & Product Lifecycle Management PDA West Coast Chapter Dinner Meeting Feb 22, 2018 Emma Ramnarine Sr. Director, Head Global Analytical Science & Technology Genentech/Roche 1 Globalization
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationSterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM
Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM DCVMN Workshop, Hyderabad, 4-8 April 2016 G. Somasundaram Associate Director - Technology Management Overview Key Regulatory
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationPrequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets
Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: information about the inspection Name of manufacturer Physical address production departments
More informationPAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets. Part 1: Concept and Principles Part 2: Mock P2 Submission
PAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets Part 1: Concept and Principles Part 2: Mock P2 Submission 1 Part 1 Concept and Principles Introduction Rationale Concept
More information